Fresenius

Fresenius Helios will be linking digitalization even more closely with its core activities in inpatient and outpatient healthcare. The company will strengthen areas such as the digitalization of clinical processes and clinical decision making, for example through the responsible use of artificial intelligence. 

Furthermore, a Digital Innovation Officer within the German Helios organization will explore innovative directions in digitalization. The implementation of digitalization processes and solutions will be the core task of the newly created function of the Head of Transformation Management at Helios. Also Quirónsalud in Spain is successfully driving forward the expansion of its leading digital processes.

In this context, Fresenius Helios will discontinue the activities of Curalie, which specializes in health apps, from the end of 2023. The Curalie subsidiaries meditec and ibs will be sold. Respective binding agreements have been signed. The business operations of the parent company Curalie GmbH and its other subsidiaries will be discontinued. The measures are in line with #FutureFresenius' intention to further focus business activities and reduce complexity.

  • Next step in implementing #FutureFresenius
  • Divestment of Eugin Group simplifies portfolio 
  • Proceeds create financial flexibility

 

Fresenius divests Eugin Group to global fertility group IVI RMA (a KKR portfolio company) and GED Capital for up to €500 million including earn-outs. Eugin is a global leader in fertility and reproduction services offering a comprehensive range of treatments and solutions for patients on their journey to parenthood. In 2022, Eugin generated sales of €227 million.

Michael Sen, CEO of Fresenius, said: “Today, we reached another milestone in the implementation of #FutureFresenius. The decision to divest Eugin comes after careful consideration, and we believe it is in the best interest of all parties involved. This will allow us to further prioritize and strengthen our efforts in our core business areas, which, in turn, will also benefit our patients. This transaction demonstrates our active portfolio management and underlines our commitment to a simplified structure, sharper focus and accelerated performance.”

“We are thrilled to add Eugin’s operations in the US and Canada to the IVI RMA group. Our ethos of compassionate, personalized care will help ensure we deliver a world-class patient experience and successful outcomes for more patients,” said Javier Sanchez Prieto, CEO of IVI RMA. “We are pleased to have partnered with GED in this creative transaction. We’re confident that our shared vision and complementary strengths make this partnership greater than the sum of its parts, allowing IVI RMA to continue its growth in North America and GED to invest behind a leading platform in Europe and Latin America.”

Subject to regulatory approvals, closing of the transaction is expected to take place in Q1 2024. 

The sale only comprises the Eugin Group. Fresenius Helios' well-established legacy business of fertility treatments in selected hospitals and outpatient centers of Quirónsalud and Helios Germany will remain with Fresenius Helios and continue to offer fertility treatments.

Lazard is acting as financial advisor and Freshfields Bruckhaus Deringer is serving as legal advisor to Fresenius.

About IVI RMA Global 
IVI RMA is a world-leading Reproductive Medicine group, backed by KKR. It is committed to providing evidence-based fertility solutions with the greatest chance of success in the shortest time necessary to patients seeking treatment anywhere in the world. IVI RMA employs more than 4,400 people across +150 locations in 14 countries. The group maintains a team of highly trained physicians as well as renowned scientists and researchers, aligned with its vision of pioneering in the field of Reproductive Medicine. 

About GED
GED is a Spanish, private, and independent asset manager, founded in 1996 by a group of professionals with large experience in the sector and with a consolidated industrial and management track record. It currently manages more than 1,000 million euros through different investment vehicles. This acquisition is the seventh transaction of the GED’s Fund VI, and the third within the health sector.
 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

  • Next step in implementing #FutureFresenius
  • Divestment of Eugin Group simplifies portfolio 
  • Proceeds create financial flexibility 

Fresenius divests Eugin Group to global fertility group IVI RMA (a KKR portfolio company) and GED Capital for up to €500 million including earn-outs. Eugin is a global leader in fertility and reproduction services offering a comprehensive range of treatments and solutions for patients on their journey to parenthood. In 2022, Eugin generated sales of €227 million.

Michael Sen, CEO of Fresenius, said: “Today, we reached another milestone in the implementation of #FutureFresenius. The decision to divest Eugin comes after careful consideration, and we believe it is in the best interest of all parties involved. This will allow us to further prioritize and strengthen our efforts in our core business areas, which, in turn, will also benefit our patients. This transaction demonstrates our active portfolio management and underlines our commitment to a simplified structure, sharper focus and accelerated performance.”

“We are thrilled to add Eugin’s operations in the US and Canada to the IVI RMA group. Our ethos of compassionate, personalized care will help ensure we deliver a world-class patient experience and successful outcomes for more patients,” said Javier Sanchez Prieto, CEO of IVI RMA. “We are pleased to have partnered with GED in this creative transaction. We’re confident that our shared vision and complementary strengths make this partnership greater than the sum of its parts, allowing IVI RMA to continue its growth in North America and GED to invest behind a leading platform in Europe and Latin America.”

Subject to regulatory approvals, closing of the transaction is expected to take place in Q1 2024. 

The sale only comprises the Eugin Group. Fresenius Helios' well-established legacy business of fertility treatments in selected hospitals and outpatient centers of Quirónsalud and Helios Germany will remain with Fresenius Helios and continue to offer fertility treatments.

Lazard is acting as financial advisor and Freshfields Bruckhaus Deringer is serving as legal advisor to Fresenius.

About IVI RMA Global 
IVI RMA is a world-leading Reproductive Medicine group, backed by KKR. It is committed to providing evidence-based fertility solutions with the greatest chance of success in the shortest time necessary to patients seeking treatment anywhere in the world. IVI RMA employs more than 4,400 people across +150 locations in 14 countries. The group maintains a team of highly trained physicians as well as renowned scientists and researchers, aligned with its vision of pioneering in the field of Reproductive Medicine. 

About GED
GED is a Spanish, private, and independent asset manager, founded in 1996 by a group of professionals with large experience in the sector and with a consolidated industrial and management track record. It currently manages more than 1,000 million euros through different investment vehicles. This acquisition is the seventh transaction of the GED’s Fund VI, and the third within the health sector.
 

Fresenius is a global healthcare group. We offer system-critical products and services for leading therapies for care of critically and chronically ill patients. The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios and the Investment Companies Fresenius Medical Care (in accordance with IFRS 5) and Fresenius Vamed.

Fresenius sells its 70 percent stake in IDCQ CRP, a co-holding entity of the hospital Clínica Ricardo Palma in Lima, Peru. The stake is acquired by entities of the Verme family which already hold a stake in the hospital, together with other local investors. 

This exit from the hospital market in Peru is a further step to strengthening #FutureFresenius and is in line with the company's intention to divest certain assets announced earlier this year. Subject to antitrust review, the all-cash transaction is expected to close in the first quarter of 2024.

Fresenius sells its 70 percent stake in IDCQ CRP, a co-holding entity of the hospital Clínica Ricardo Palma in Lima, Peru. The stake is acquired by entities of the Verme family which already hold a stake in the hospital, together with other local investors. 

This exit from the hospital market in Peru is a further step to strengthening #FutureFresenius and is in line with the company's intention to divest certain assets announced earlier this year. Subject to antitrust review, the all-cash transaction is expected to close in the first quarter of 2024.

The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2024 in Germany, has been set at 4.22%. Due to cost inflation, the rate of change will most likely mark the lower limit of the price increase for hospital treatments for 2024 in Germany. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.

The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2024 in Germany, has been set at 4.22%. Due to cost inflation, the rate of change will most likely mark the lower limit of the price increase for hospital treatments for 2024 in Germany. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.

The price increase for hospital services in Germany has been set at 3.45 % for 2023. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

The price increase for hospital services in Germany has been set at 3.45 % for 2023. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

Subscribe to Fresenius Helios